Swaminathan Giridharan, MD
Endocrinology · Brooklyn, NYNPI 1578530770
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 228 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$888
- Amneal Pharmaceuticals LLC$687
- Amgen$650
- Eisai Inc.$439
- AbbVie$425
- plus $2K from 19 others
What the payments were for
- Consulting fees$3505%
- Food & beverage$6,53195%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 43 | $1,349 |
| Novo Nordisk | 50 | $888 |
| Amneal Pharmaceuticals LLC | 31 | $687 |
| Amgen(2 entities) | 20 | $650 |
| Eisai Inc. | 4 | $439 |
| AbbVie | 23 | $425 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $350 |
| Sanofi-aventis U.S. LLC | 14 | $322 |
| Mannkind Corporation | 5 | $298 |
| Xeris Pharmaceuticals, Inc. | 2 | $270 |
| Neurelis, Inc. | 1 | $150 |
| Amarin Pharma, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $121 |
| Catalyst Pharmaceuticals, Inc. | 1 | $113 |
| PTC Therapeutics, Inc. | 1 | $99 |
| Medtronic | 3 | $87 |
| Lilly USA, LLC | 4 | $83 |
| Corcept Therapeutics | 3 | $82 |
| Astellas Pharma US Inc | 3 | $81 |
| Zogenix Inc. | 1 | $76 |
| Bayer | 3 | $69 |
| Radius Health, Inc. | 2 | $53 |
| Vistapharm, Inc. | 2 | $36 |
| Merck | 1 | $19 |
| Shield Therapeutics Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,886 in reported general payments places this provider in the 85th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $82,882 |
| JardianceEmpagliflozin | 49 | $44,707 |
| MounjaroTirzepatide | 38 | $42,581 |
| KerendiaFinerenone | 28 | $37,628 |
| FarxigaDapagliflozin Propanediol | 38 | $32,544 |
| RybelsusSemaglutide | 29 | $32,133 |
| JanuviaSitagliptin Phosphate | 18 | $25,247 |
| Cinacalcet Hcl | 17 | $22,582 |
| TrulicityDulaglutide | 15 | $21,344 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $18,345 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $13,752 |
| TradjentaLinagliptin | 11 | $9,771 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $9,700 |
| TirosintLevothyroxine Sodium | 26 | $8,093 |
| LivaloPitavastatin Calcium | 12 | $6,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $888 | $115,01497 claims |
| Lilly USA, LLCMounjaro, Trulicity | $83 | $63,92553 claims |
| MerckJanuvia, Janumet | $19 | $43,59132 claims |
| BayerKerendia | $69 | $37,62828 claims |
| AstraZenecaFarxiga | $1,349 | $32,54438 claims |
| AbbVieSynthroid | $425 | $5,24559 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $687 | $2,664173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 endocrinology providers in New York.
Other endocrinology in Brooklyn
- Elia KassabBrooklyn$1K
- Alastair ThomsonBrooklyn$0
- Christine RestaBrooklyn$0
- Ahmed SiddiquiBrooklyn$0
- Ewelina Bryll-PerzanBrooklyn$0
- Philip RabitoNew York$712K
- Perry HersonWilliston Park$364K
- Olga LeonardiNew York$10K
- Isabela RomaoNew Hyde Park$10K
- Stephanie CharlesWest Nyack$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.